Opioid Induced Constipation Market - Global Forecast 2026-2032

Senior healthcare and pharmaceutical leaders are facing new clinical and commercial pressures as the opioid induced constipation market evolves and treatment innovation reshapes patient management strategies. Stakeholders require rigorous, actionable insights to address shifting payer and patient priorities in a competitive and regulation-rich environment.

Market Snapshot: Opioid Induced Constipation Market Growth and Trends

The opioid induced constipation market grew from USD 75.03 million in 2025 to USD 79.32 million in 2026. It is poised for sustained expansion at a CAGR of 6.93%, expected to reach USD 119.94 million by 2032. This momentum reflects increased opioid use across care settings and rising demand for therapies that balance analgesic efficacy with improved gastrointestinal outcomes. Leading pharmaceutical companies and healthcare networks alike are responding to the expanded and differentiated therapeutic landscape.

Scope & Segmentation

This report provides a granular analysis of key segments and drivers, including:

Product Types: Combination therapies, traditional laxatives, and peripherally acting mu-opioid receptor antagonists, with sub-segmentation into osmotic laxatives, stimulant laxatives, stool softeners, and agents such as alvimopan, methylnaltrexone, naldemedine, and naloxegol.
Formulation Attributes: Liquid and solid oral forms (solutions, suspensions, tablets, capsules) and rectal delivery (enemas, suppositories).
Patient and Payer Use Cases: Acute and chronic management, adherence optimization, and population-specific needs, especially for those with swallowing difficulties or requiring tailored dosing.
Geographic Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, each with unique payer frameworks, regulatory requirements, and adoption drivers.
Stakeholder Segments: Pharmaceutical manufacturers, clinical prescribers, payers, procurement organizations, and health system leaders.

Key Takeaways

Pharmacologic innovation and novel mechanisms are broadening the therapeutic toolkit available to clinicians, with an emphasis on agents that target opioid-induced motility disruption without undermining analgesia.
Formulation variety—including liquids, solids, enemas, and suppositories—enables more tailored approaches, directly affecting adherence rates and patient satisfaction across diverse care environments.
Shifting evidence demands and payer scrutiny highlight the need for pragmatic trial data, comparative studies, and analysis of health economic outcomes to support product adoption.
Regionally distinct reimbursement and regulatory pathways require nuanced market entry strategies, as different healthcare systems value comparative effectiveness, local evidence, or affordability.
Strategic partnerships between manufacturers, specialty pharmacies, and health systems enhance both patient access and formulary positioning, while digital support tools encourage sustained therapy adherence.
Supply resilience is increasingly critical as manufacturers reevaluate sourcing and logistics in response to changing global trade and tariff pressures.

Tariff Impact and Commercial Adaptation

Global trade fluctuations and evolving tariffs now influence the economics of opioid induced constipation therapies. Changes in import duties and trade policies are prompting manufacturers to reevaluate supplier networks, manufacturing locations, and inventory models to sustain supply continuity and price competitiveness. Payers and procurement leaders are intensifying their focus on cost containment, total care impact, and downstream utilization reduction, raising the bar for evidence supporting new therapies.

Methodology & Data Sources

Findings combine data from randomized controlled trials, observational studies, regulatory reviews, guideline analyses, and documented real-world studies. Insights are further refined through expert interviews with clinicians, payer representatives, and supply chain specialists, ensuring multidimensional relevance. Quality appraisal and source transparency anchor all conclusions.

Why This Report Matters

Identifies where mechanism, formulation, and route of administration align with clinical and payer needs to unlock segment-specific growth opportunities.
Clarifies how shifting reimbursement landscapes and real-world evidence demands influence successful product adoption and access in distinct global markets.
Supports business leaders in navigating supply, tariff, and procurement complexities to protect patient access and operational margins.

Conclusion

The opioid induced constipation market represents a dynamic intersection of patient expectations, payer demands, and regulatory nuances. Informed strategies on clinical differentiation, real-world evidence, and supply resilience are essential for sustained success and patient impact.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Opioid Induced Constipation Market, by Product Type

8.1. Combination Therapies
8.2. Laxatives
8.2.1. Osmotic Laxatives
8.2.2. Stimulant Laxatives
8.2.3. Stool Softeners
8.3. Peripherally Acting Mu-Opioid Receptor Antagonists
8.3.1. Alvimopan
8.3.2. Methylnaltrexone
8.3.3. Naldemedine
8.3.4. Naloxegol

9. Opioid Induced Constipation Market, by Route of Administration

9.1. Oral
9.2. Rectal

10. Opioid Induced Constipation Market, by Distribution Channel

10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies
10.4. Specialty Pharmacies

11. Opioid Induced Constipation Market, by Region

11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific

12. Opioid Induced Constipation Market, by Group

12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO

13. Opioid Induced Constipation Market, by Country

13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea

14. United States Opioid Induced Constipation Market
15. China Opioid Induced Constipation Market

16. Competitive Landscape

16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. AstraZeneca PLC
16.6. Bausch Health Companies Inc.
16.7. Cubist Pharmaceuticals LLC
16.8. Daewoong Pharmaceutical Co., Ltd.
16.9. Egalet Corporation
16.10. GlaxoSmithKline PLC
16.11. Ironwood Pharmaceuticals, Inc.
16.12. Johnson & Johnson
16.13. Merck & Co., Inc.
16.14. Mundipharma International Limited
16.15. Nektar Therapeutics
16.16. Pfizer Inc.
16.17. Pharmaceuticals Co., Ltd.
16.18. Purdue Pharma L.P.
16.19. Shionogi & Co., Ltd.
16.20. Takeda Pharmaceutical Company Limited
16.21. Trevena, Inc.
16.22. Vertex Pharmaceuticals Incorporated

List of Figures

FIGURE 1. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 83. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 84. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. EUROPE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 94. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 95. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 96. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 107. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 108. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 109. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. ASEAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 113. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 114. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 115. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. GCC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 125. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 126. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 127. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. BRICS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 132. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 133. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. G7 OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 137. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 138. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 139. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. NATO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 149. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 150. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
TABLE 151. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 152. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Opioid Induced Constipation market report include:

AstraZeneca PLC
Bausch Health Companies Inc.
Cubist Pharmaceuticals LLC
Daewoong Pharmaceutical Co., Ltd.
Egalet Corporation
GlaxoSmithKline PLC
Ironwood Pharmaceuticals, Inc.
Johnson & Johnson
Merck & Co., Inc.
Mundipharma International Limited
Nektar Therapeutics
Pfizer Inc.
Pharmaceuticals Co., Ltd.
Purdue Pharma L.P.
Shionogi & Co., Ltd.
Takeda Pharmaceutical Company Limited
Trevena, Inc.
Vertex Pharmaceuticals Incorporated

Table Information

Report Attribute	Details
No. of Pages	187
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 79.32 Million
Forecasted Market Value ( USD ) by 2032	$ 119.94 Million
Compound Annual Growth Rate	6.9%
Regions Covered	Global
No. of Companies Mentioned	19

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: Opioid Induced Constipation Market Growth and Trends

Scope & Segmentation

Key Takeaways

Tariff Impact and Commercial Adaptation

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast - 2034

Opioid-Induced Constipation Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

Opioid-Induced Constipation Treatment Market Report 2025

Constipation Treatment Market Report 2025

Constipation Laxative Market Report: Trends, Forecast and Competitive Analysis to 2031